Cafepharma Today

May 19 2025 - Regeneron wins bid to buy 23andMe out of bankruptcy
Regeneron wins bid to buy 23andMe out of bankruptcy
Amid US investment push, Lilly eyes Houston as potential home for $5.9B API plant
Japan follows UK in GSK's comeback tour for Blenrep
FDA clears Novavax’s COVID-19 vaccine with usage restrictions
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts
BioSpace
Wednesday, December 18, 2024 - 11:12am
tags:
Regeneron, Bayer, retinal vein occlusion, Eyelea
Sensorion encouraged by deafness gene therapy data
Pharmaphorum
Wednesday, December 18, 2024 - 11:10am
tags:
Sensorion, otoferlin-related hearing loss, hearing loss, gene therapy, clinical trials, SENS-501
Merck targets 2025 RSV season with antibody now under FDA review
BioPharma Dive
Wednesday, December 18, 2024 - 11:09am
tags:
Merck, RSV, clesrovimab, infants
FDA grants fast-track status to combination mRNA flu and COVID-19 vaccine candidates
Beckers Hospital Review
Tuesday, December 17, 2024 - 12:09pm
tags:
Sanofi, Novavax, COVID-19, vaccines, FDA, fast track, MRNA, Flu
Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025
Fierce Pharma
Tuesday, December 17, 2024 - 12:07pm
tags:
Pfizer, Inflation Reduction Act, M&A
Sandoz shells out $275M in latest effort to move past 'legacy' price-fixing litigation
Fierce Pharma
Tuesday, December 17, 2024 - 12:03pm
tags:
Sandoz, price fixing, legal
PFA to surpass radiofrequency ablation in 2025: Citi survey
Medtech Dive
Tuesday, December 17, 2024 - 12:01pm
tags:
Medtech, pulsed field ablation, radiofrequency ablation, Medtronic, Boston Scientific, JNJ
Biomea's diabetes drug improves glucose control 3 months after FDA hold lifted
Fierce Biotech
Tuesday, December 17, 2024 - 12:00pm
tags:
Bioma Fusion, diabetes, icovamenib
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
BioPharma Dive
Tuesday, December 17, 2024 - 11:59am
tags:
Sanofi, Teva Pharmaceutical, IBD, Merck, Roche, duvakitug
UCB's orchestra hits dud note: Novartis-partnered Parkinson's asset fails phase 2
Fierce Biotech
Tuesday, December 17, 2024 - 11:58am
tags:
UCB Pharma, Novartis, Parkinson's Disease, minzasolmin, clinical trials
A biotech’s race to tackle the most severe hepatitis
Pharma Voice
Tuesday, December 17, 2024 - 11:56am
tags:
Bluejay Therapeutics, hepatitis D
MindMed doses first subject in trial of tablets for generalized anxiety disorder
Clinical Trials Arena
Tuesday, December 17, 2024 - 11:54am
tags:
Mind Medicine, MM120, generalized anxiety disorder
FDA dents J&J's blockbuster hopes for Rybrevant
Pharmaphorum
Tuesday, December 17, 2024 - 11:53am
tags:
JNJ, Rybrevant, FDA
End of the line for Merck's TIGIT, LAG-3 cancer drugs
Pharmaphorum
Tuesday, December 17, 2024 - 11:52am
tags:
Merck, vibostolimab, favezelimab, anti-TIGIT, immuno-oncology
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century
BioSpace
Monday, December 16, 2024 - 11:18pm
tags:
Bristol Myers Squibb, Immatics, Century Therapeutics
Generative AI has ‘potential to revolutionize clinical development’
Clinical Trials Arena
Monday, December 16, 2024 - 11:16pm
tags:
generative AI, artificial intelligence, clinical trials, drug development
Jazz to search for new chief as CEO plans retirement
BioPharma Dive
Monday, December 16, 2024 - 11:15pm
tags:
Jazz Pharma, Pharma CEOs, Bruce Cozadd
Novo Nordisk blueprints $1.2B rare disease production plant in Denmark, where it plans to hire on 400 new staffers
Fierce Pharma
Monday, December 16, 2024 - 11:44am
tags:
Novo Nordisk, Denmark, drug manufacturing
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Yahoo/Benzinga
Monday, December 16, 2024 - 11:43am
tags:
Bicycle Therapeutics, urothelial cancer, zelenectide pevedotin
Novo Nordisk's Ozempic reportedly linked to vision loss in new study
Yahoo Finance
Monday, December 16, 2024 - 11:39am
tags:
Novo Nordisk, Ozempic, vision loss

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.